Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1 Locke, F. L., Ghobadi, A., Jacobson, C. A., Jacobsen, E., Miklos, D. B., Lekakis, L. J., Braunschweig, I., Oluwole, O. O., Lin, Y., Siddiqi, T., Deol, A., Reagan, P. M., Farooq, U., Bot, A., Jiang, Y., Rossi, J. M., Xue, A., Go, W. Y., Neelapu, S. S. CIG MEDIA GROUP, LP. 2018: S277–S278

View details for Web of Science ID 000444343400254